Analytik Jena Announces Financial Figures for the First Quarter 2012/2013

Analytik Jena AG / Analytik Jena Announces Financial Figures for the First Quarter 2012/2013 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. * Operating profit below expectations at EUR 1.23 m * Total revenue growth of 4.9 % satisfactory and heavily influenced by the Analytical Instrumentation core business * Revenue growth of 19.5 % in Asia reinforces market positioning * Negative financial result due in particular to currency effects Jena (Germany), February 14, 2013 - Analytik Jena AG (Prime Standard: AJA, ISIN: DE0005213508) hereby announces the final figures for the first quarter of the 2012/2013 financial year. According to the figures, the manufacturer of laboratory, bioanalytical and analytical measuring technology generated consolidated revenue of EUR 24.31 m (previous year: EUR 23.18 m), thus achieving a year-on-year revenue upturn of 4.9 %. The Group achieved an operating profit of EUR 1.23 m (previous year: EUR 1.89 m), despite the challenging environment. Due especially to currency effects and a negative contribution to earnings from the 49.0 % subsidiary AJZ Engineering, the Group posted a consolidated net loss for the period of EUR -0.04 m (previous year: EUR 1.46 m). Earnings per share amounted to EUR -0.01 (previous year: EUR 0.25). "Analytik Jena AG began the new financial year 2012/2013 with growth in consolidated revenue. Nevertheless, we are not satisfied with our earnings in the quarter. In the first few months of the new financial year, we posted some weaker revenue and gross margins of subsidiaries, while we also had to compensate for exchange rate influences. Even continued strong and growing business in China and the Far East did not balance this out", said Klaus Berka, CEO of Analytik Jena AG. "Nevertheless, we anticipate that this weaker start to financial year 2012/2013 will balance itself out over the course of the period as a whole, and that we will again achieve our aim of finishing the year with increased revenue and earnings in our operating business." Revenue Development and Segments Segment performance presented a mixed picture. While the Analytical Instrumentation unit again showed itself to be a strong pillar of the Company and generated solid year-on-year revenue growth of 11.9 % to EUR 15.77 m (previous year: EUR 14.09 m), in the Life Science segment - which currently still focuses much more intensively on the European and American markets and is thus confronted with the negative economic influences more heavily in comparison - revenue declined by 7.5 % to EUR 7.35 m (previous year: EUR 7.95 m). Especially the two subsidiaries Biometra GmbH and CyBio AG, despite still showing positive operational figures, generated weaker revenue and earnings, while business unit revenue in the parent company was raised by 29.6 %. The Optics unit posted slight revenue growth of 4.5 % to EUR 1.20 m (previous year: EUR 1.14 m), but was also forced to absorb higher costs due to high expenditure for OEM product manufacturing. In Optics, the IWA exhibition taking place in Nuremberg at the beginning of March is expected to have a significant positive effect. Considered in terms of regions, the Asia region made the most significant contribution to revenue growth for the Analytik Jena Group. In Asia, revenue increased from EUR 7.81 m to EUR 9.33 m year on year, a rise of 19.5 %. In Germany and the rest of Europe, revenue was also up slightly by 2.8 % and 2.5 % respectively, while revenue in America fell considerably by 27.4 %. The export share increased slightly to 70.7 % in the first three months of the new financial year (previous year: 70.1 %). Earnings Operating profit of the Analytik Jena Group totaled EUR 1.23 m in the first quarter (previous year: EUR 1.89 m), which was 35.2 % lower than that achieved in the same period of the previous year. The EBIT margin declined accordingly, falling from 8.2 % to 5.0 %. Analytik Jena AG posted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 2.26 m in the past quarter (previous year: EUR 2.89 m), which is equivalent to a decline of 21.7 %. Owing to the unfavorable development of the USD and YEN and the resulting exchange rate losses (compared to exchange rate gains in the same period of the previous year), as well as a negative result from the investment in subsidiary AJZ Engineering, the financial result was impacted negatively. Analytik Jena thus posted earnings before taxes (EBT) of EUR -0.06 m (previous year: EUR 2.06 m). Overall, the Analytik Jena Group posted a consolidated net loss for the period of EUR -0.04 m (previous year: EUR 1.46 m). Earnings per share amounted to EUR - 0.01 (previous year: EUR 0.25). Changes in Statement of Financial Position The Group's total assets as of the balance sheet date on December 31, 2012 fell slightly by 3.3 % to EUR 102.17 m (September 30, 2012: EUR 105.65 m). In the reporting period, Analytik Jena showed almost unchanged equity of EUR 46.16 m (September 30, 2012: EUR 46.25 m). The equity ratio rose accordingly from 43.8 % as of September 30, 2012 to 45.2 % as of December 31, 2012. Cash and cash equivalents totaled EUR 20.34 m as of the end of the reporting period (September 30, 2012: EUR 21.53 m). At the same time, Analytik Jena recorded operating cash flow of EUR 1.57 m in the reporting period. Human Resources As of the balance sheet date, the Group employed 815 staff, including 46 trainees (previous year: 807 employees, including 39 trainees). Outlook Development in the Analytical Instrumentation business unit will largely depend on the future global economic situation, whereby the largest growth prospects exist in developing and emerging countries, above all China, where Analytik Jena AG has an excellent market position. However, steadily rising costs in China and a growing currency risk must also be taken into consideration. Irrespective of these variables, the Executive Board expects stable business in this core area overall. The Company expects revenue and earnings to stabilize in the Life Science business unit. The subsidiaries, including Japan, are anticipated to contribute to this as well as China. In the Optics consumer segment, which has not yet returned to its former strength, the Company's main focus is on expanding the new OEM business area as well as traditional observation optics and optical sights. By tradition, the IWA leading exhibition held in Nuremberg at the beginning of March will once again have a significant positive effect on order and revenue development in the segment in the current financial year. Thanks also to a series of new or modified products, Analytik Jena expects this unit to regain momentum. The Company anticipates a stable second quarter overall. As is usual, Analytik Jena will announce its outlook for the entire financial year at the Annual General Meeting on April 23, 2013. Further Information The full financial report can be accessed at MonthReport_1213.pdf. Contact: André Muehlig Analytik Jena AG Konrad-Zuse-Strasse 1 07745 Jena/Germany Tel. +49 3641 779281 Email: This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Analytik Jena AG via Thomson Reuters ONE [HUG#1678125]